Pacific Biosciences of California, Inc. (PACB) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 18 analysts28.6% Above Target
PACB trades 28.6% above Wall Street's consensus target of $1.00.
Current Price$1.40
Average Target$1.00
Low$1.00
Median$1.00
High$1.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth+2.5%
(Low)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PACB achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 18 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PACB Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Pacific Biosciences of California, Inc. (PACB) has a Wall Street consensus price target of $1.00, based on estimates from 18 covering analysts. With the stock currently trading at $1.40, this represents a potential downside of -28.6%. The company has a market capitalization of $435M.
Analyst price targets range from a low of $1.00 to a high of $1.00, representing a 0% spread in expectations. The median target of $1.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PACB trades at a trailing P/E of -0.8x. Analysts expect EPS to grow +2.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+4.3%
Industry Consensus
Avg Forward P/E
25.2x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
 BFLYButterfly Network, Inc. | $2.3B | $8.90 | $5.42 | -39.1% | Buy | — | 7 |
 CDNACareDx, Inc | $1.4B | $26.18 | $27.00 | +3.1% | Buy | 28.0x | 13 |
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
 DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
 AAgilent Technologies, Inc. | $35.9B | $127.06 | $154.75 | +21.8% | Buy | 21.0x | 41 |
 BIOBio-Rad Laboratories, Inc. | $7.6B | $282.44 | $321.67 | +13.9% | Buy | 31.2x | 14 |
 BEAMBeam Therapeutics Inc. | $3.5B | $34.14 | $48.00 | +40.6% | Buy | — | 27 |
 TXG10x Genomics, Inc. | $4.4B | $34.76 | $22.43 | -35.5% | Hold | — | 22 |
 TWSTTwist Bioscience Corporation | $5.5B | $87.56 | $75.00 | -14.3% | Buy | — | 13 |
PACB — Frequently Asked Questions
Quick answers to the most common questions about buying PACB stock.
What is the PACB stock price target for 2026?
PACB's consensus price target is $1, -28.6% below the current price of $1.4. The 18 analysts tracking PACB see downside risk at present valuations.
Is PACB a buy, sell, or hold?
PACB has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $1 implies -28.6% downside from current levels.
Is PACB stock overvalued or undervalued?
PACB's current price is $1.4 with a consensus target of $1 (-28.6% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can PACB stock go?
The most bullish Wall Street analyst has a price target of $1 for PACB, while the most conservative target is $1. The consensus of $1 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PACB stock?
PACB is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PACB stock forecast?
The 12-month PACB stock forecast based on 18 Wall Street analysts shows a consensus price target of $1, with estimates ranging from $1 (bear case) to $1 (bull case). The median consensus rating is "Buy".
Should I buy PACB stock?
Analysts are cautious on PACB, with 1 Sell ratings and a price target of $1 (-28.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PACB price targets vary so much?
PACB analyst price targets range from $1 to $1, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare